RGEN – Repligen Corporation
Float Short %
6.84
Margin Of Safety %
-13
Put/Call OI Ratio
2.28
EPS Next Q Diff
0.13
EPS Last/This Y
2.15
EPS This/Next Y
0.5
Price
124.78
Target Price
180.53
Analyst Recom
1.59
Performance Q
3.6
Relative Volume
0.95
Beta
1.07
Ticker: RGEN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | RGEN | 121.67 | 2.64 | 0.01 | 8910 |
| 2025-07-28 | RGEN | 119.7 | 1.34 | 0.35 | 11304 |
| 2025-07-29 | RGEN | 125.35 | 1.35 | 0.09 | 11519 |
| 2025-07-30 | RGEN | 122.88 | 1.40 | 0.15 | 11372 |
| 2025-07-31 | RGEN | 117.08 | 1.41 | 0.24 | 11361 |
| 2025-08-01 | RGEN | 118.94 | 1.40 | 1.29 | 11434 |
| 2025-08-04 | RGEN | 116.5 | 1.40 | 0.12 | 11531 |
| 2025-08-05 | RGEN | 115.88 | 1.39 | 0.85 | 11525 |
| 2025-08-06 | RGEN | 112.03 | 1.39 | 0.48 | 11502 |
| 2025-08-07 | RGEN | 113.56 | 1.39 | 1.13 | 11507 |
| 2025-08-08 | RGEN | 111.4 | 1.40 | 0.57 | 11505 |
| 2025-08-11 | RGEN | 111.92 | 1.40 | 29.10 | 11508 |
| 2025-08-12 | RGEN | 121.41 | 1.52 | 0.16 | 12134 |
| 2025-08-13 | RGEN | 127.15 | 1.51 | 0.12 | 12184 |
| 2025-08-14 | RGEN | 126.67 | 1.54 | 0.48 | 12122 |
| 2025-08-15 | RGEN | 124.32 | 1.54 | 0.07 | 12121 |
| 2025-08-18 | RGEN | 124.03 | 4.70 | 1.03 | 8379 |
| 2025-08-19 | RGEN | 123.62 | 4.38 | 1.64 | 8663 |
| 2025-08-20 | RGEN | 121.51 | 4.37 | 1.00 | 8695 |
| 2025-08-21 | RGEN | 119.62 | 4.37 | 0.02 | 8696 |
| 2025-08-22 | RGEN | 124.79 | 2.28 | 0.84 | 10206 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | RGEN | 121.74 | 18.1 | 66.2 | 1.68 |
| 2025-07-28 | RGEN | 119.85 | 18.1 | 65.3 | 1.68 |
| 2025-07-29 | RGEN | 125.30 | 18.1 | 69.3 | 1.68 |
| 2025-07-30 | RGEN | 122.85 | 18.1 | 65.0 | 1.68 |
| 2025-07-31 | RGEN | 117.07 | -7.3 | 63.2 | 1.68 |
| 2025-08-01 | RGEN | 118.91 | -3.9 | 69.8 | 1.69 |
| 2025-08-04 | RGEN | 116.50 | -3.9 | 67.4 | 1.69 |
| 2025-08-05 | RGEN | 115.88 | -3.9 | 68.4 | 1.69 |
| 2025-08-06 | RGEN | 112.11 | -3.7 | 66.6 | 1.69 |
| 2025-08-07 | RGEN | 113.52 | -3.7 | 69.6 | 1.69 |
| 2025-08-08 | RGEN | 111.43 | -3.7 | 67.5 | 1.69 |
| 2025-08-11 | RGEN | 111.93 | -3.7 | 59.6 | 1.69 |
| 2025-08-12 | RGEN | 121.32 | -3.7 | 64.9 | 1.69 |
| 2025-08-13 | RGEN | 127.15 | -3.8 | 62.5 | 1.69 |
| 2025-08-14 | RGEN | 126.74 | -3.8 | 59.1 | 1.69 |
| 2025-08-15 | RGEN | 124.24 | -3.8 | 58.0 | 1.69 |
| 2025-08-18 | RGEN | 124.05 | -3.8 | 59.2 | 1.69 |
| 2025-08-19 | RGEN | 123.50 | -3.8 | 59.0 | 1.69 |
| 2025-08-20 | RGEN | 121.56 | -3.8 | 58.3 | 1.69 |
| 2025-08-21 | RGEN | 119.68 | -3.8 | 58.3 | 1.69 |
| 2025-08-22 | RGEN | 124.78 | -3.8 | 62.2 | 1.69 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | RGEN | -1.70 | 2.12 | 6.40 |
| 2025-07-28 | RGEN | -1.70 | 2.06 | 6.40 |
| 2025-07-29 | RGEN | -1.70 | 2.06 | 6.40 |
| 2025-07-30 | RGEN | -1.70 | 2.06 | 6.40 |
| 2025-07-31 | RGEN | -1.70 | 2.06 | 6.40 |
| 2025-08-01 | RGEN | -1.70 | 2.06 | 6.40 |
| 2025-08-04 | RGEN | -1.70 | 1.92 | 6.40 |
| 2025-08-05 | RGEN | -1.70 | 1.92 | 6.40 |
| 2025-08-06 | RGEN | -1.70 | 1.92 | 6.40 |
| 2025-08-07 | RGEN | -1.70 | 1.92 | 6.40 |
| 2025-08-08 | RGEN | -1.70 | 1.92 | 6.40 |
| 2025-08-11 | RGEN | -1.69 | 1.76 | 6.39 |
| 2025-08-12 | RGEN | -1.64 | 1.76 | 6.84 |
| 2025-08-13 | RGEN | -1.64 | 1.76 | 6.84 |
| 2025-08-14 | RGEN | -1.64 | 1.76 | 6.84 |
| 2025-08-15 | RGEN | -1.64 | 1.76 | 6.84 |
| 2025-08-18 | RGEN | -1.64 | 1.57 | 6.84 |
| 2025-08-19 | RGEN | -1.64 | 1.57 | 6.84 |
| 2025-08-20 | RGEN | -1.64 | 1.57 | 6.84 |
| 2025-08-21 | RGEN | -1.64 | 1.57 | 6.84 |
| 2025-08-22 | RGEN | -1.64 | 1.57 | 6.84 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.37
Avg. EPS Est. Current Quarter
0.41
Avg. EPS Est. Next Quarter
0.5
Insider Transactions
-1.64
Institutional Transactions
1.57
Beta
1.07
Average Sales Estimate Current Quarter
182
Average Sales Estimate Next Quarter
193
Fair Value
107.97
Quality Score
54
Growth Score
73
Sentiment Score
41
Actual DrawDown %
61.9
Max Drawdown 5-Year %
-66.4
Target Price
180.53
P/E
Forward P/E
56.86
PEG
P/S
10.42
P/B
3.4
P/Free Cash Flow
66.26
EPS
-0.25
Average EPS Est. Cur. Y
1.69
EPS Next Y. (Est.)
2.18
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-2.05
Relative Volume
0.95
Return on Equity vs Sector %
-25.4
Return on Equity vs Industry %
-9.5
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
62.2
Repligen CorporationSector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 1778
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
stock quote shares RGEN – Repligen Corporation Stock Price stock today
news today RGEN – Repligen Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch RGEN – Repligen Corporation yahoo finance google finance
stock history RGEN – Repligen Corporation invest stock market
stock prices RGEN premarket after hours
ticker RGEN fair value insiders trading